AbbVie and Genmab Report Late-Stage Trial Failure for Lymphoma Drug Epcoritamab
AbbVie (ABBV) and Genmab (GMAB) announced that their jointly developed lymphoma drug epcoritamab failed to meet the primary endpoint in a late-stage trial. The setback could impact investor confidence in the treatment's potential for diffuse large B-cell lymphoma.
Topics: biotech bispecific_antibody diffuse_large_b_cell_lymphoma oncology